Abbott May Be Doing The Right Thing At The Wrong Time Seeking Alpha Beyond that is a joint venture with Biogen Idec (BIIB) for daclizumab in the increasingly-crowded next-gen multiple sclerosis space and a slate of Hep C drugs that don't seem so obviously better than those at Roche, Bristol-Myers, GlaxoSmithKline (GSK) ... |
